Severe pigment dispersion after iris-claw phakic intraocular lens implantation

Galvis, Virgilio; Carreño, Néstor I.; Tello, Alejandro; Laiton, Andrea N

doi:10.4103/ijo.ijo_743_17

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cardinal risks associated with implantation of them are long-term endothelial cell loss (particularly in iris-claw pIOLs), cataract formation, pigment dispersion and raised intraocular pressure. [7][8][9][10][11][12] Some newer pIOLs models have emerged during the last few years, but there is no evidence regarding their long-term safety and efficacy with a follow-up time of 5 years or longer. [13][14][15][16][17] The current paper demonstrates 1-year visual outcomes of a newer type of phakic IOL (Refractive Intraocular Lens (RIL), Appasamy Associates Inc.) in eyes with moderate to high myopia.…”

mentioning

confidence: 99%

Safety and Efficacy of a New Posterior Chamber Phakic Intraocular Lens in Cases of High Myopia: Early Results

Subudhi¹,

Patro²,

Agarwal³

et al. 2020

OPTH

View full text Add to dashboard Cite

Purpose: To demonstrate the visual outcomes of a foldable, hydroxy ethyl-methacrylate, single-piece, posterior chamber phakic intraocular lens (pIOL). Study Type: Retrospective study. Materials and Methods: Patients presenting with moderate to high myopia who underwent surgical correction with a posterior chamber phakic IOL (refractive intraocular lens, phakic intraocular lens, Appasamy Associates, Chennai, India) were retrospectively reviewed. Only patients with at least one-year follow-up were included. Manifest refraction, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), endothelial cell density (ECD), and pIOL vault were analyzed 1, 3, 6, and 12 months after surgery. Intraoperative and postoperative events were recorded in all cases. Results: The study included 30 eyes from 15 patients. The mean patient age was 25.8 ± 3 years. The spherical equivalent of manifest refraction was −11.47 ± 4.38 D preoperatively and −0.44 ± 0.55 D postoperatively. The preoperative CDVA was 0.17 ± 0.12 logMAR. The postoperative UDVA was 0.053 ± 0.11 logMAR (min: −0.17 and max: 0.2) and 0.019 ± 0.091 logMAR (min: −0.17 and max: 0.2) at the end of 1 month and 6 months, respectively. At the end of the 12-month visit, the postoperative UDVA was 0.032 ± 0.094, and the safety index was 2.42. The mean ECD was 2639 cells/mm 2 (min: 2389 and max: 2993 with SD: 139.53) at the preoperative visit and 2445 cells/mm 2 (min: 2050 and max: 2701) at the 12-month visit (5.8% loss, p less than 0.001). ECD loss from 6 months to 12 months was not statistically significant. No significant cataract formation, significant endothelial cell loss, glaucoma, uveitis, or any other vision-threatening complication were observed. Conclusion:Based on postoperative experience, we found that RIL phakic IOLs are safe and effective for treating high myopia at short-term follow-up.

show abstract

mentioning

confidence: 99%

Safety and Efficacy of a New Posterior Chamber Phakic Intraocular Lens in Cases of High Myopia: Early Results

Subudhi¹,

Patro²,

Agarwal³

et al. 2020

OPTH

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7][8] These complications include uveitis with anterior or posterior synechias, and pigment dispersion possibly related to the contact or closeness of the pIOL with intraocular structures. 4,[8][9][10][11][12][13][14] , The original model of Artiflex I pIOL (Ophtec, Groningen, The Netherlands) launched in 2004 and then withdrawn from the market, had some of these complications due to presumed too shallow haptic angle but the newer currently available Artiflex pIOL (model 401, Ophtec, Groningen, The Netherlands) has a new configuration, the step-vaulted haptic in high range powers (−2.00 to −14.50 D). 4,[9][10][11] Herein we describe a case with acute posterior synechia formation implantation in the patient's left eye, following bilateral simultaneous Artiflex pIOL (model 401) foldable silicone iris fixated pIOL.…”

Section: Introductionmentioning

confidence: 99%

Anterior Uveitis with Posterior Synechia and Iris Atrophy Following Implantation of a Phakic Intraocular Lens

Mohammadpour¹,

Mazloumi²,

Khorrami-Nejad³

2020

IMCRJ

View full text Add to dashboard Cite

Purpose: To describe a case with acute postoperative uveitis, posterior synechia and iris atrophy following iris-claw phakic intraocular lens (pIOL) implantation. Methods: A case report. Results: A 26-year-old man with high myopia had implantation of a −14.0 diopter, foldable, iris-claw Artiflex (model 401) anterior chamber pIOL (Ophtec B.V.) in both eyes. On the third postoperative day, the patient had significant postoperative inflammation in the left eye and received topical steroids and mydriatic eye drops. On the fifth postoperative day, the right eye had a round pupil and centered pIOL, but the left eye had an atrophic iris and dilated pupil with significant posterior synechias over the inferior half of the pupil. Despite intensive topical steroid application, the synechias remained one year after surgery. Conclusion: Severe uveitis with posterior synechia can occur after iris-claw pIOL implantation. We hypothesized that excessive iris tissue enclavation in the pIOLs haptics and large iridotomies may be an associated factor.

show abstract

IOL repositioning using iris sutures: a safe and effective technique

Caporossi¹

2019

Int J Ophthalmol

View full text Add to dashboard Cite

Severe pigment dispersion after iris-claw phakic intraocular lens implantation

Cited by 3 publications

References 7 publications

<p>Safety and Efficacy of a New Posterior Chamber Phakic Intraocular Lens in Cases of High Myopia: Early Results</p>

<p>Safety and Efficacy of a New Posterior Chamber Phakic Intraocular Lens in Cases of High Myopia: Early Results</p>

<p>Anterior Uveitis with Posterior Synechia and Iris Atrophy Following Implantation of a Phakic Intraocular Lens</p>

IOL repositioning using iris sutures: a safe and effective technique

Contact Info

Product

Resources

About